MaxCyte, Inc. announced on January 23, 2024, Cenk Sumen, Ph.D.?s employment as chief scientific officer of the company ended. Dr. Sumen will maintain a relationship with the Company as a member of the company?s Scientific Advisory Board.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
370 GBX | -2.12% | -6.33% | +4.96% |
May. 08 | MaxCyte Shares Rise Sharply After Q1 Results Beat | MT |
May. 08 | MaxCyte shares rise amid double-digit revenue increase | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.96% | 497M | |
+12.95% | 227B | |
+13.61% | 192B | |
+18.03% | 136B | |
+28.27% | 108B | |
+1.67% | 64.07B | |
+17.44% | 52.1B | |
+7.04% | 51.87B | |
+10.73% | 44.33B | |
+5.78% | 36.75B |
- Stock Market
- Equities
- MXCT Stock
- News MaxCyte, Inc.
- MaxCyte, Inc. Announces Departure of Cenk Sumen as Chief Scientific Officer